Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 11/20 | 0.46 |
| ▸ | AURKA | O14965 | 5/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234731 | 0.88 | CDK1 (0.46) | CDK1SYKAURKAJAK2EGFR | |
| SCHEMBL19297752 | 0.86 | AURKA (0.53) | CDK1SYKAURKAJAK2EGFR | |
| SCHEMBL12389639 | 0.84 | SYK (0.58) | CDK1SYKEGFR | |
| SCHEMBL19297743 | 0.81 | SYK (0.63) | SYKAURKA | |
| SCHEMBL19297726 | 0.81 | EGFR (0.48) | CDK1SYKAURKAJAK2EGFR | |
| SCHEMBL19297732 | 0.81 | SYK (0.55) | CDK1SYKAURKAJAK2EGFR | |
| SCHEMBL14837242 | 0.80 | SYK (0.56) | CDK1SYKAURKAJAK2EGFR | |
| SCHEMBL19297748 | 0.79 | BCL6 (0.58) | SYKAURKAEGFR | |
| SCHEMBL12389645 | 0.79 | SYK (0.62) | CDK1SYKAURKAJAK2EGFR | |
| Trifluoroacetic Acid SCHEMBL19297711 | 0.78 | SYK (0.54) | CDK1SYKJAK2EGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010181-B1 | METHODS OF TREATING CELL PROLIFERATIVE DISORDERS BY USING PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | claimed |
| US-8481521-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481521-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120245127-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245127-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8227455-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227455-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-7962290-B1 | Identification of pharmacophores from co-crystals of spleen tyrosine kinase (SYK) and SYK ligands | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7962290-B1 | Identification of pharmacophores from co-crystals of spleen tyrosine kinase (SYK) and SYK ligands | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2010181-B1 | METHODS OF TREATING CELL PROLIFERATIVE DISORDERS BY USING PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2010181-B1 | METHODS OF TREATING CELL PROLIFERATIVE DISORDERS BY USING PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2009003136-A1 | SUBSTITUTED PYRIMIDINE-2, 4 -DIAMINES FOR TREATING CELL PROLIFERATIVE DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2007124221-A1 | METHODS OF TREATING CELL PROLIFERATIVE DISORDERS BY USING PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245127-A1 | Methods of Treating Cell Proliferative Disorders | MKI67, SYK, TP53 | CDK1 107/4885SYK 2/4885AURKA 723/4885 |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | MKI67, RET, HRAS | CDK1 90/4885SYK 3090/4885AURKA 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.